Clinical trial • Phase I • Oncology

Clinical trial in Malignant neoplasm (solid tumors)

Phase I trial for Malignant neoplasm (solid tumors). 82 participants.

Overview

Trial Therapeutic Area
Oncology
Trial Disease
Malignant neoplasm (solid tumors)
Trial Stage
Phase I

Key dates

Initial CTIS Submission Date
22-10-2024
First CTIS Authorization Date
24-02-2025

Trial design

Phase I trial across 6 sites in Spain, Poland.

Target Sample Size
82

Recruitment

Planned Sample Size
82
Recruitment Window Months
35

Geography

Total Number Of Sites
6
Total Number Of Participants
30

Spain

Earliest CTIS Part Ii Submission Date
27-01-2025
Latest Decision Or Authorization Date
09-03-2026
Processing Time Days
406
Number Of Sites
4
Number Of Participants
22

Sites

Site Name
Hospital Universitario Hm Sanchinarro
Department Name
Oncology
Contact Person Name
Irene Moreno Candilejo
Contact Person Email
irene.moreno@startmadrid.com
Site Name
University Hospital Virgen Del Rocio S.L.
Department Name
Oncology
Contact Person Name
Alejandro Falcon Gonzalez
Site Name
Institut Catala D'oncologia
Department Name
Oncology
Contact Person Name
Jose Carlos Ruffinelli Rodriguez
Contact Person Email
jruffinelli@iconcologia.net
Site Name
Hospital Universitari Vall D Hebron
Department Name
Oncology
Contact Person Name
Elena Garralda Cabanas
Contact Person Email
egarralda@vhio.net

Poland

Earliest CTIS Part Ii Submission Date
24-01-2025
Latest Decision Or Authorization Date
07-03-2026
Processing Time Days
407
Number Of Sites
2
Number Of Participants
8

Sites

Site Name
Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy
Department Name
Oddział Badań Wczesnych Faz
Contact Person Name
Iwona Ługowska
Contact Person Email
obwf@nio.gov.pl
Site Name
Uniwersyteckie Centrum Kliniczne
Department Name
Centrum Wsparcia Badań Klinicznych UCK Ośrodek Badań Klinicznych Wczesnych Faz
Contact Person Name
Rafał Dziadziuszko
Contact Person Email
obkwf@uck.gda.pl

Sponsor

Primary sponsor

Full Name
Merck Sharp & Dohme LLC
Organisation Type
Pharmaceutical company
Country Of Registered Address
United States

Related trials

Other published trials that may interest you.